Today's Editor's Pick Check out this week's pick, free for a limited time.  In October 2019, a Philadelphia jury delivered an $8 billion verdict against Johnson & Johnson for its improper marketing of the antipsychotic drug Risperdal as a treatment for some mental ... |
|---|
|
|---|
| Get your all access pass. Instantly gain access to over 2,000 articles written exclusively for P/C Carrier Executives |
|---|
|
|---|
|
|
